Advertisement

Brain Iron Uptake and Transport in Animal Model of Iron Deficiency, Tardive Dyskinesia and Neurodegenerative Diseases

  • M. B. H. Youdim
  • K. L. Leenders
  • D. Ben-Shachar

Abstract

Abnormality of iron either its increase or decrease in the tissue is associated with some of the most devastating diseases in human. Until very recently very little attention was paid to iron metabolism in the brain. Reduction in brain iron is thought to cause cognitive and learning impairment in infants and young children (Youdim et al.,1989) (Yehuda and Youdim, 1989; Youdim and Yehuda, 2000) Indeed, in animal studies in which nutritionally iron deficiency was induced in young rats (28–80 day old) brain iron was reduced by 30–40%. These animals exhibit learning deficits in Y-water maze and Morris water tank. Iron supplementation restored iron levels cognitive and behavioral deficits to normal. In contrast, if iron deficiency is induced in newborn rats (10 day old) iron supplementation could not reverse brain iron and the learning deficits even after long-term treatment.

Keywords

Iron Deficiency Tardive Dyskinesia Lipoic Acid Liver Iron Atypical Antipsychotic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreassen, O. A. and Jorgensen, H. A. (2000). “Neurotoxicity associated with neurolepticinduced oral dyskinesias in rats. Implications for tardive dyskinesia?” Progress in Neurobiology 61(5): 525–541.PubMedCrossRefGoogle Scholar
  2. Ben-Shachar, D., Ashkenazi, R. and Youdim, M. B. (1986). “Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats.” International Journal of Developmental Neuroscience 4(1): 81–88.PubMedCrossRefGoogle Scholar
  3. Ben-Shachar, D., Livne, E., Spanier, I., Leenders, K. L. and Youdim, M. B. (1994). “Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeC13 uptake.” Journal of Neurochemistry 62(3): 1112–1118.PubMedCrossRefGoogle Scholar
  4. Ben-Shachar, D., Livne, E., Spanier, I., Zuk, R. and Youdim, M. B. (1993). “Iron modulates neuroleptic-induced effects related to the dopaminergic system.” Israel Journal of Medical Sciences 29(9): 587–592.PubMedGoogle Scholar
  5. Ben-Shachar, D., Pinhassi, B. and Youdim, M. B. (1991). “Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.” European Journal of Pharmacology 202(2): 177–183.PubMedCrossRefGoogle Scholar
  6. Ben-Shachar, D., Yehuda, S., Finberg, J. P., Spanier, I. and Youdim, M. B. (1988). “Selective alteration in blood-brain barrier and insulin transport in iron-deficient rats.” Journal of Neurochemistry 50(5): 1434–1437.PubMedCrossRefGoogle Scholar
  7. Borg, D. and Cotzias, G. C. (1962). “Interaction of trace metal with phenothiazine drug derivatives. II. Formation of free radicals.” Proceedings of the National Academy of Sciences of the United States of America 48: 623–642.PubMedCrossRefGoogle Scholar
  8. Cadet, J. L., Lohr, J. B. and Jeste, D. V. (1986). “Free radicals and tardive dyskinesia.” Trends in Neurosciences(9): 107–108.CrossRefGoogle Scholar
  9. Demasi, M. and Bechara, E. J. (1996). “Chlorpromazine stimulatory effect on iron uptake by rat brain synaptosomes.” Biochemical Pharmacology 51(3): 331–337.PubMedCrossRefGoogle Scholar
  10. Dwork, A. J., Lawler, G., Zybert, P. A., Durkin, M., Osman, M., Willson, N. and Barkai, A. I. (1990). “An autoradiographic study of the uptake and distribution of iron by the brain of the young rat.” Brain Research 518(1-2): 31–39.PubMedCrossRefGoogle Scholar
  11. Dwork, A. J., Schon, E. A. and Herbert, J. (1988). “Nonidentical distribution of transferrin and ferric iron in human brain.” Neuroscience 27(1): 333–345.PubMedCrossRefGoogle Scholar
  12. Elkashef, A. M. and Wyatt, R. J. (1999). “Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.” Schizophrenia Bulletin 25(4): 731–740.PubMedCrossRefGoogle Scholar
  13. Gerlach, M., Ben-Shachar, D., Riederer, P. and Youdim, M. B. H. (1994). “Altered brain metabolism of iron as a cause of neurodegenerative diseases?” Journal of Neurochemistry 793(3): 793–807.Google Scholar
  14. Gerlach, M., Double, K., Riederer, P., Hirsch, E., Jellinger, K., Jenner, P., Trautwein, A. and Youdim, M. B. (1997). “Iron in the Parkinsonian substantia nigra [letter; comment].” Movement Disorders 12(2): 258–260.PubMedGoogle Scholar
  15. Gupta, S., Mosnik, D., Black, D. W., Berry, S. and Masand, P. S. (1999). “Tardive dyskinesia: review of treatments past, present, and future.” Annals of Clinical Psychiatry 11(4): 257–266.PubMedGoogle Scholar
  16. Halliwell, B. (1992). “Reactive oxygen species and the central nervous system.” Journal of Neurochemistry 59(5): 1609–1623.PubMedCrossRefGoogle Scholar
  17. Hill, J. M. (1985). “Iron concentration reduced in ventral pallidum, globus pallidus, and substantia nigra by GABA-transaminase inhibitor, gamma-vinyl GABA.” Brain Research 342(1): 18–25.PubMedCrossRefGoogle Scholar
  18. Jeding, I., Evans, P. J., Akanmu, D., Dexter, D., Spencer, J. D., Aruoma, O. I., Jenner, P. and Halliwell, B. (1995). “Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs.” Biochemical Pharmacology 49(3): 359–365.PubMedCrossRefGoogle Scholar
  19. Jellinger, K. A. (1999). “The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson’s disease.” Drugs Aging 14: 115–140.PubMedCrossRefGoogle Scholar
  20. Jenner, P. and Olanow, C. W. (1996). “Oxidative stress and the pathogenesis of Parkinson’s disease.” Neurology 47(0028-3878): 161–170.CrossRefGoogle Scholar
  21. Leenders, K. L., Antonini, A., Schwarzbach, R., Smith-Jones, P., Reist, H., Ben-Shachar, D., Youdim, M. and Henn, V. (1994). “Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol.” Journal of Neural Transmission. Supplementum 43: 123–132.PubMedGoogle Scholar
  22. Linert, W., Herlinger, E., Jameson, R. F., Kienzl, E., Jellinger, K. and Youdim, M. B. (1996). “Dopamine, 6-hydroxydopamine, iron, and dioxygen—their mutual interactions and possible implication in the development of Parkinson’s disease.” Biochimica et Biophysica Acta 1316(3): 160–168.PubMedCrossRefGoogle Scholar
  23. Penatti, C. A., Gurgueira, S. A., Bechara, E. J. and Demasi, M. (1998). “Neuroleptic drugstimulated iron uptake by synaptosome preparations of rat cerebral cortex.” Biochimica et Biophysica Acta 1407(1): 61–68.PubMedCrossRefGoogle Scholar
  24. Rajan, K. S., Manian, A. A., Davis, J. M. and Skripkus, A. (1974). “Studies on the metal chelation of chlorpromazine and its hydroxylated metabolites.” Advances in Biochemical Psychopharmacology 9(0): 571–591.PubMedGoogle Scholar
  25. Roy, D., Pathak, D. N. and Singh, R. (1984). “Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain.” Journal of Neurochemistry 42(3): 628–633.PubMedCrossRefGoogle Scholar
  26. Sachdev, P., Saharov, T. and Cathcart, S. (1999). “The preventative role of antioxidants (Selegiline and vitamin E) in a rat model of tardive dyskinesia.” Biological Psychiatry 46(12): 1672–1681.PubMedCrossRefGoogle Scholar
  27. Shamir, E., Barak, Y., Plopsky, I., Zisapel, N., Elizur, A. and Weizman, A. (2000). “Is melatonin treatment effective for tardive dyskinesia?” Journal of Clinical Psychiatry 61(8): 556–558.PubMedCrossRefGoogle Scholar
  28. Shoham, S. and Youdim, M. B. H. (2000). “Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases.” Cellular and Molecular Biology 46(4): 743–760.PubMedGoogle Scholar
  29. Soares, K. V. and McGrath, J. J. (2000). “Vitamin E for neuroleptic-induced tardive dyskinesia.” Cochrane Database of Systematic Reviews [computer file](2): CD000209.Google Scholar
  30. Vatassery, G. T., Bauer, T. and Dysken, M. (1999). “High doses of vitamin E in the treatment of disorders of the central nervous system in the aged [see comments].” American Journal of Clinical Nutrition 70(5): 793–801.PubMedGoogle Scholar
  31. Yehuda, S. and Youdim, M. B. (1989). “Brain iron: a lesson from animal models.” American Journal of Clinical Nutrition 50(3 Suppl): 618–625; discussion 625-619.PubMedGoogle Scholar
  32. Youdim, M. B., Ben-Shachar, D., Ashkenazi, R. and Yehuda, S. (1983). “Brain iron and dopamine receptor function.” Advances in Biochemical Psychopharmacology 37: 309–321.PubMedGoogle Scholar
  33. Youdim, M. B., Ben-Shachar, D. and Yehuda, S. (1989). “Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior [published erratum appears in Am J Clin Nutr 1990 Feb;5(12): 319].” American Journal of Clinical Nutrition 50(3 Suppl): 607–615; discussion 615-607.PubMedGoogle Scholar
  34. Youdim, M. B., Grunblatt, E. and Mandel, S. (1999). “The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson’s disease with iron chelators.” Annals of the New York Academy of Sciences 890: 7–25.PubMedCrossRefGoogle Scholar
  35. Youdim, M. B. H., Ben-Shachar, D. and Riederer, P. (1993). “Parkinson’s disease and increased iron in substantia nigra zona compacta.” Movement Disorders 8: 1–12.PubMedCrossRefGoogle Scholar
  36. Youdim, M. B. H. and Yehuda, S. (2000). “The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine-opiate system.” Cellular and Molecular Biology 46(3): 491–500.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • M. B. H. Youdim
    • 2
  • K. L. Leenders
    • 3
  • D. Ben-Shachar
    • 1
  1. 1.Medicine, Eve Topf and NPF Centers for Neurodegenerative Diseases ResearchIsrael
  2. 2.Laboratory of Psychobiology, Department of Psychiatry, Faculty of MedicineTechnion and Rambam Medical CenterHaifaIsrael
  3. 3.Department of NeurologyUniversity of GroningenGroningenNetherlands

Personalised recommendations